David Sinclair Supplement Protocol

Why Sinclair takes it: NAD+ precursor; 'cellular energy & DNA repair'; prefers NMN over NR; stack cornerstone — Lifespan (2019); Diamandis interview (Jun 2025)

What the evidence says: Reliably raises blood NAD+ in humans, but 2024 meta-analyses (513 and 342 participants) found no improvement in glucose, lipids or insulin resistance, and there are zero human lifespan or hard-outcome data. The best 'positive' RCT showed only a modest 6-minute-walk gain and was industry-funded.

Why Sinclair takes it: Sirtuin (SIRT1) activator; claimed to work synergistically with NMN — Lifespan (2019); Rhonda Patrick & Ben Greenfield interviews

What the evidence says: The core mechanism failed independent replication: the original sirtuin 'activation' was an in-vitro assay artifact, and GSK wound down its ~720M USD Sirtris program. A 2025 GRADE meta-analysis of 11 RCTs found no effect on SIRT1; bioavailability is poor and there are no human outcome data. The NMN-synergy claim is purely preclinical.

Why Sinclair takes it: Senolytic; clears senescent 'zombie' cells — Diamandis interview (Jun 2025)

What the evidence says: The senolytic reputation rests on a 2018 mouse study; human trials (incl. Mayo Clinic) are ongoing and so far inconclusive. Poor oral bioavailability, and no completed RCT shows it clears senescent cells or improves any aging outcome in people.

Why Sinclair takes it: Autophagy inducer; cellular recycling — Multiple interviews

What the evidence says: Higher dietary spermidine tracked with lower mortality in one cohort (Bruneck) but not another (Takayama, with a hint of higher cancer mortality in women). The 12-month SmartAge RCT missed its primary memory endpoint. No trial shows the 1-2 mg pill induces autophagy or extends life.

Why Sinclair takes it: AMPK activator; used to replace metformin; lowers glucose — Diamandis interview (Jun 2025)

What the evidence says: Strong RCT support for the metabolic claim: meta-analyses (46 and 50 RCTs) show meaningful drops in HbA1c (~0.7%), fasting glucose, LDL and triglycerides. But there is NO human longevity or cardiovascular-outcome data, and the 'Nature's Ozempic' label is hype – effects are far smaller than GLP-1 drugs. GI upset and CYP drug interactions are common.

Why Sinclair takes it: Fibrinolytic enzyme; claimed '36% plaque reduction' — Diamandis interview (Jun 2025)

What the evidence says: The '36% plaque' figure traces to one small, unreplicated study. The only rigorous long-term trial – a 3-year, 265-person RCT (Hodis 2021) – found a null effect on carotid plaque, arterial stiffness and every blood marker measured. Carries a theoretical bleeding risk with anticoagulants.

Why Sinclair takes it: Antioxidant; mitochondrial support — Diamandis interview (Jun 2025)

What the evidence says: No human trial has tested whether ALA slows aging – the claim is purely cell/animal mechanism. Its only solid human evidence is symptom relief in diabetic neuropathy; antioxidant biomarker effects are small and inconsistent. Can lower blood glucose (additive with diabetes drugs).

Why Sinclair takes it: Anti-inflammatory; cardiovascular & cognitive support — Multiple interviews

What the evidence says: The two biggest primary-prevention RCTs (VITAL, ASCEND) were null for cardiovascular events and mortality. A real 25% event reduction (REDUCE-IT) applied only to high-dose prescription EPA in statin-treated patients with high triglycerides. High-dose fish oil modestly raises atrial-fibrillation and bleeding risk.

Why Sinclair takes it: Mitochondrial support; replaces statin-depleted CoQ10 — Multiple interviews

What the evidence says: For the stated use – fixing statin muscle symptoms – the better 2020 meta-analysis found no benefit and no drop in creatine kinase. The strong CoQ10 evidence (Q-SYMBIO, halved mortality) is in heart failure, not a healthy statin user. Very safe; can reduce warfarin's effect.

Why Sinclair takes it: Cancer risk reduction; anti-inflammatory — Multiple interviews

What the evidence says: Top-tier evidence that argues AGAINST this use: in the 19,114-person ASPREE trial, aspirin gave no cardiovascular benefit in primary prevention, did NOT reduce cancer, and increased major bleeding and all-cause mortality (driven by cancer deaths) in healthy older adults. For a healthy person without established CVD, the net effect is harm.

Why Sinclair takes it: Immune, bone, gene expression; paired with K2 — Multiple interviews

What the evidence says: VITAL (25,871 people) showed 2,000 IU/day did not cut cardiovascular events, cancer incidence or fractures in mostly-replete adults. The honest positive signal is narrow: ~13-16% lower cancer mortality with daily dosing, plus real benefit when correcting a measured deficiency. Test your level rather than mega-dose.

Why Sinclair takes it: Directs calcium to bone not arteries; D3 companion — Multiple interviews

What the evidence says: Human evidence is almost all surrogate: K2 activates matrix Gla protein and one RCT improved arterial stiffness, but the hard-endpoint AVADEC trial found no slowing of valve/coronary calcification and no reduction in events. Cheap and safe, but the 'moves calcium' claim is unproven on outcomes that matter.

Why Sinclair takes it: Familial cholesterol risk; claims possible cancer/dementia benefit — Joe Rogan podcast

What the evidence says: The cardiovascular benefit is as solid as clinical evidence gets: CTT meta-analyses (170,000+ patients) show each 1 mmol/L LDL drop cuts major vascular events ~21% and all-cause mortality ~10% – so high-intensity statin for genuine familial hypercholesterolaemia is a proven, lifespan-relevant medical use. The separate cancer/dementia claims are NOT established (same data show no cancer effect).

Why Sinclair takes it: mTOR inhibitor; 'most geroprotective molecule in animals' — Diamandis interview (Jun 2025)

What the evidence says: The single most robust lifespan-extender in mice (NIA ITP, replicated across three sites), but there is NO human longevity evidence: the 48-week PEARL RCT missed its primary endpoint and other human trials are immune/surrogate only. Real immunosuppression and infection risk.

Why Sinclair takes it: AMPK activator; largely replaced by berberine — Diamandis interview (Jun 2025); Lifespan

What the evidence says: A proven diabetes drug, but its anti-aging benefit in non-diabetics is unproven: the purpose-built TAME trial is only a design paper, the famous observational survival signal is confounded, and a 2019 RCT showed metformin can blunt the mitochondrial and fitness gains from exercise in older adults.